Trial Profile

Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HER2-specific chimeric antigen receptor T cell therapy-Seattle Children's Therapeutics (Primary)
Indications CNS cancer
Focus Adverse reactions; Therapeutic Use
Acronyms BrainChild01

Most Recent Events

11 Dec 2024 Planned primary completion date changed from 26 Jul 2024 to 26 Jul 2025.
14 Dec 2023 Status changed from recruiting to active, no longer recruiting.
18 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com